Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 6/20 | 0.45 |
| ▸ | FLT3 | P36888 | 3/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | FGFR2 | P21802 | 5/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2927706 | 0.99 | FGFR1 (0.44) | FGFR1FLT3HDAC1FGFR2POLB | |
| SCHEMBL5449603 | 0.92 | MEN1 (0.49) | FLT3NPC1RAB9ASMN1; SMN2AURKA | |
| Hydrochloric Acid SCHEMBL2927668 | 0.91 | MEN1 (0.48) | FLT3NPC1RAB9ASMN1; SMN2AURKA | |
| SCHEMBL2922698 | 0.91 | KMT2A (0.47) | FGFR1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL3903873 | 0.89 | FGFR1 (0.42) | FGFR1FLT3SMN1; SMN2AURKAMEN1 | |
| Hydrochloric Acid SCHEMBL2923186 | 0.88 | FGFR1 (0.42) | FGFR1FLT3SMN1; SMN2AURKAMEN1 | |
| Hydrochloric Acid SCHEMBL2929385 | 0.88 | KMT2A (0.38) | FGFR1FLT3HDAC1NPC1RAB9A | |
| SCHEMBL2921040 | 0.88 | FGFR1 (0.40) | FGFR1FLT3NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2928661 | 0.88 | KMT2A (0.38) | FLT3HDAC1NPC1RAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL3899899 | 0.88 | FGFR1 (0.40) | FGFR1FLT3NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050032839-A1 | Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PHARMACIA ITALIA S.P.A. (IT) | 2005-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032839-A1 | Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | MAP3K3, MAP3K19, MAP3K9 | FGFR1 585/4885FLT3 250/4885HDAC1 891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.